<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Breast Cancer Research &#187; Congress</title>
	<atom:link href="http://breastcancerresearch.info/tag/congress/feed" rel="self" type="application/rss+xml" />
	<link>http://breastcancerresearch.info</link>
	<description>Breast Cancer Treatment, Prevention, Screening And Procedures</description>
	<lastBuildDate>Tue, 21 Feb 2012 00:35:52 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Pulmonary Fibrosis Research Enhancement Act Re-Introduced in U.S. Congress</title>
		<link>http://breastcancerresearch.info/pulmonary-fibrosis-research-enhancement-act-re-introduced-in-u-s-congress.html</link>
		<comments>http://breastcancerresearch.info/pulmonary-fibrosis-research-enhancement-act-re-introduced-in-u-s-congress.html#comments</comments>
		<pubDate>Sat, 16 Jul 2011 23:20:00 +0000</pubDate>
		<dc:creator></dc:creator>
				<category><![CDATA[Breast Cancer Information]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Enhancement]]></category>
		<category><![CDATA[Fibrosis]]></category>
		<category><![CDATA[Pulmonary]]></category>
		<category><![CDATA[ReIntroduced]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[U.S.]]></category>

		<guid isPermaLink="false">http://breastcancerresearch.info/pulmonary-fibrosis-research-enhancement-act-re-introduced-in-u-s-congress.html</guid>
		<description><![CDATA[Pulmonary Fibrosis Research Enhancement Act Re-Introduced in U.S. Congress Contact: Teresa Barnes, Coalition for Pulmonary Fibrosis, +1-303-521-4080, tbarnes@coalitionforpf.org Read more on PR Newswire via Yahoo! News]]></description>
			<content:encoded><![CDATA[<p><b>Pulmonary Fibrosis Research Enhancement Act Re-Introduced in U.S. Congress</b><br />
Contact: Teresa Barnes, Coalition for Pulmonary Fibrosis, +1-303-521-4080, tbarnes@coalitionforpf.org</p>
<p>Read more on <a href="http://news.yahoo.com/pulmonary-fibrosis-research-enhancement-act-introduced-u-congress-213106306.html">PR Newswire via Yahoo! News</a><br/><br/></p>
]]></content:encoded>
			<wfw:commentRss>http://breastcancerresearch.info/pulmonary-fibrosis-research-enhancement-act-re-introduced-in-u-s-congress.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress</title>
		<link>http://breastcancerresearch.info/oncologists-discuss-about-nccn-updated-guidelines-at-4th-annual-asia-scientific-congress.html</link>
		<comments>http://breastcancerresearch.info/oncologists-discuss-about-nccn-updated-guidelines-at-4th-annual-asia-scientific-congress.html#comments</comments>
		<pubDate>Sat, 30 Apr 2011 23:24:29 +0000</pubDate>
		<dc:creator></dc:creator>
				<category><![CDATA[Breast Cancer Awareness]]></category>
		<category><![CDATA[About]]></category>
		<category><![CDATA[annual]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Discuss]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Nccn]]></category>
		<category><![CDATA[Oncologists]]></category>
		<category><![CDATA[Scientific]]></category>
		<category><![CDATA[UPDATED]]></category>

		<guid isPermaLink="false">http://breastcancerresearch.info/oncologists-discuss-about-nccn-updated-guidelines-at-4th-annual-asia-scientific-congress.html</guid>
		<description><![CDATA[Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers. Read more on [...]]]></description>
			<content:encoded><![CDATA[<p><b>Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress</b><br />
More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers.</p>
<p>Read more on <a href="http://www.news-medical.net/news/20110425/Oncologists-discuss-about-NCCN-updated-guidelines-at-4th-Annual-Asia-Scientific-Congress.aspx">News-Medical-Net</a><br/><br/></p>
]]></content:encoded>
			<wfw:commentRss>http://breastcancerresearch.info/oncologists-discuss-about-nccn-updated-guidelines-at-4th-annual-asia-scientific-congress.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress</title>
		<link>http://breastcancerresearch.info/allos-therapeutics-announces-folotyn%c2%ae-data-presentation-at-the-35th-esmo-congress.html</link>
		<comments>http://breastcancerresearch.info/allos-therapeutics-announces-folotyn%c2%ae-data-presentation-at-the-35th-esmo-congress.html#comments</comments>
		<pubDate>Sun, 12 Sep 2010 00:36:38 +0000</pubDate>
		<dc:creator></dc:creator>
				<category><![CDATA[High Risk Breast Cancer]]></category>
		<category><![CDATA[35th]]></category>
		<category><![CDATA[Allos]]></category>
		<category><![CDATA[Announces]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Data]]></category>
		<category><![CDATA[ESMO]]></category>
		<category><![CDATA[FOLOTYN®]]></category>
		<category><![CDATA[Presentation]]></category>
		<category><![CDATA[Therapeutics']]></category>

		<guid isPermaLink="false">http://breastcancerresearch.info/allos-therapeutics-announces-folotyn%c2%ae-data-presentation-at-the-35th-esmo-congress.html</guid>
		<description><![CDATA[Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress WESTMINSTER, Colo.&#8211;(BUSINESS WIRE)&#8211;Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that results from the Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical [...]]]></description>
			<content:encoded><![CDATA[<p><b>Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress</b><br />
WESTMINSTER, Colo.&#8211;(BUSINESS WIRE)&#8211;Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that results from the Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress — Milan, Italy from October 8-12, 2010 &#8230;</p>
<p>Read more on <a href="http://www.businesswire.com/news/home/20100909006475/en">Business Wire</a><br/><br/></p>
]]></content:encoded>
			<wfw:commentRss>http://breastcancerresearch.info/allos-therapeutics-announces-folotyn%c2%ae-data-presentation-at-the-35th-esmo-congress.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress</title>
		<link>http://breastcancerresearch.info/ph-ii-data-of-perifosine-capecitabine-in-metastatic-crc-to-be-presented-at-gastrointestinal-cancer-congress.html</link>
		<comments>http://breastcancerresearch.info/ph-ii-data-of-perifosine-capecitabine-in-metastatic-crc-to-be-presented-at-gastrointestinal-cancer-congress.html#comments</comments>
		<pubDate>Sun, 04 Jul 2010 23:23:40 +0000</pubDate>
		<dc:creator></dc:creator>
				<category><![CDATA[Breast Cancer Chemotherapy]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[capecitabine]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Data]]></category>
		<category><![CDATA[gastrointestinal]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[perifosine]]></category>
		<category><![CDATA[presented]]></category>

		<guid isPermaLink="false">http://breastcancerresearch.info/ph-ii-data-of-perifosine-capecitabine-in-metastatic-crc-to-be-presented-at-gastrointestinal-cancer-congress.html</guid>
		<description><![CDATA[Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled &#8220;Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line [...]]]></description>
			<content:encoded><![CDATA[<p><b>Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress</b><br />
Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled &#8220;Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC&#8221; has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in &#8230;</p>
<p>Read more on <a href="http://www.news-medical.net/news/20100630/Ph-II-data-of-perifosine-2b-capecitabine-in-metastatic-CRC-to-be-presented-at-gastrointestinal-cancer-congress.aspx">News-Medical-Net</a><br/><br/></p>
]]></content:encoded>
			<wfw:commentRss>http://breastcancerresearch.info/ph-ii-data-of-perifosine-capecitabine-in-metastatic-crc-to-be-presented-at-gastrointestinal-cancer-congress.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>IOF WCO-ECCEO10 osteoporosis congress opens in Florence, Italy</title>
		<link>http://breastcancerresearch.info/iof-wco-ecceo10-osteoporosis-congress-opens-in-florence-italy.html</link>
		<comments>http://breastcancerresearch.info/iof-wco-ecceo10-osteoporosis-congress-opens-in-florence-italy.html#comments</comments>
		<pubDate>Fri, 07 May 2010 23:09:28 +0000</pubDate>
		<dc:creator></dc:creator>
				<category><![CDATA[Breast Cancer Treatment Options]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Florence]]></category>
		<category><![CDATA[Italy]]></category>
		<category><![CDATA[opens]]></category>
		<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[WCOECCEO10]]></category>

		<guid isPermaLink="false">http://breastcancerresearch.info/iof-wco-ecceo10-osteoporosis-congress-opens-in-florence-italy.html</guid>
		<description><![CDATA[IOF WCO-ECCEO10 osteoporosis congress opens in Florence, Italy A record number of researchers and clinicians from some 100 countries gathered today in Florence, Italy to share new information about osteoporosis, a serious chronic disease which leads to weakened bones and fractures in as many as one in three women and one in five men over [...]]]></description>
			<content:encoded><![CDATA[<p><b>IOF WCO-ECCEO10 osteoporosis congress opens in Florence, Italy</b><br />
A record number of researchers and clinicians from some 100 countries gathered today in Florence, Italy to share new information about osteoporosis, a serious chronic disease which leads to weakened bones and fractures in as many as one in three women and one in five men over the age of fifty.</p>
<p>Read more on <a href="http://www.news-medical.net/news/20100506/IOF-WCO-ECCEO10-osteoporosis-congress-opens-in-Florence-Italy.aspx">News-Medical-Net</a><br/><br/></p>
]]></content:encoded>
			<wfw:commentRss>http://breastcancerresearch.info/iof-wco-ecceo10-osteoporosis-congress-opens-in-florence-italy.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

